成人伯基特淋巴瘤接受CODOX-M/IVAC联合或不联合利妥昔单抗治疗的真实世界疗效优异
这项基于加拿大不列颠哥伦比亚省15年人群的分析纳入81例成人伯基特淋巴瘤患者,接受改良CODOX-M/IVAC方案联合或不联合利妥昔单抗治疗,5年无进展生存率和总生存率分别为75%和77%,无治疗相关死亡,完成方案者及60岁以下患者生存显著更优。
要点
- 81例成人伯基特淋巴瘤患者接受CODOX-M/IVAC联合或不联合利妥昔单抗,5年无进展生存率75%、总生存率77%,无治疗相关死亡。
- 按方案完成治疗者(n=38)5年无进展生存率86%(P=0.04)、总生存率92%(P=0.008),显著优于未完成者。
- 60岁以下患者5年无进展生存率82%(P=0.005)、总生存率86%(P=0.002),多因素分析中年龄仍与生存显著相关。
核心结论
- 这项大型真实世界分析显示,成人伯基特淋巴瘤接受CODOX-M/IVAC联合或不联合利妥昔单抗治疗的生存结局优异,与临床试验相当。
- 这些结果可为新方案引入临床实践时比较伯基特淋巴瘤的治愈性治疗提供基准。
研究设计与样本
- 研究为基于人群的生存分析,纳入加拿大不列颠哥伦比亚省15年间81例成人伯基特淋巴瘤患者。
- 治疗方案为改良CODOX-M/IVAC(环磷酰胺、长春新碱、多柔比星、泼尼松及大剂量甲氨蝶呤;异环磷酰胺、美司钠、依托泊苷、阿糖胞苷及鞘内甲氨蝶呤)联合或不联合利妥昔单抗。
- 81例患者中包括8例中枢神经系统受累和18例人类免疫缺陷病毒相关伯基特淋巴瘤。
主要发现
- 81例患者5年无进展生存率为75%(95%CI:63-83%),5年总生存率为77%(95%CI:66-85%),无治疗相关死亡。
- 按方案完成治疗者(n=38)5年无进展生存率86%(P=0.04)、总生存率92%(P=0.008),显著优于未按方案完成者。
- 60岁以下患者5年无进展生存率82%(P=0.005)、总生存率86%(P=0.002),多因素分析中年龄与无进展生存(HR 3.36,P=0.018)和总生存(HR 4.03,P=0.012)显著相关。
- 多因素分析中,纳入大剂量全身甲氨蝶呤也显著影响总生存(HR 0.28,P=0.025)。
- 首次缓解期接受干细胞移植对总生存或无进展生存无影响。
关键数值与推荐
- 5年无进展生存率75%(95%CI:63-83%),5年总生存率77%(95%CI:66-85%)。
- 按方案完成治疗者(n=38)5年无进展生存率86%(P=0.04)、总生存率92%(P=0.008)。
- 60岁以下患者5年无进展生存率82%(P=0.005)、总生存率86%(P=0.002)。
- 多因素分析:年龄与无进展生存(HR 3.36,P=0.018)和总生存(HR 4.03,P=0.012)相关;大剂量全身甲氨蝶呤与总生存相关(HR 0.28,P=0.025)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined population-based survival outcomes of adults with BL treated with a modified combination of cyclophosphamide, vincristine, doxorubicin, prednisone and systemic high-dose methotrexate (MTX) (CODOX-M) with IVAC (ifosfamide, mesna, etoposide, cytarabine and intrathecal MTX) (CODOX-M/IVAC) ± rituximab over a 15-year period in British Columbia. For the 81 patients identified (including 8 with CNS involvement and 18 with human immunodeficiency virus-associated BL), 5-year progression-free survival (PFS) and overall survival (OS) were 75% [95% confidence interval (CI): 63-83%] and 77% (95% CI: 66-85%), respectively, with no treatment-related deaths. Those who completed the regimen per protocol (n = 38) had significantly improved 5-year PFS 86% (P = 0·04) and OS 92% (P = 0·008), as did those under 60 years with 5-year PFS 82% (P = 0·005) and OS 86% (P = 0·002), which remained significant in multivariate analysis [PFS: hazard ratio (HR) 3·36, P = 0·018; OS HR 4·03, P = 0·012]. Incorporation of high-dose systemic methotrexate also significantly affected multivariate survival outcomes (OS HR 0·28, P = 0·025). Stem cell transplant in first remission had no effect on OS or PFS. This large, real-world analysis of BL patients treated with CODOX-M/IVAC ± rituximab demonstrates excellent survival outcomes comparable to clinical trials. These results help to serve as a benchmark when comparing curative therapies for BL patients as novel regimens are incorporated into clinical practice.
引用
- Zhu KY, Song KW, Connors JM, et al. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol. 2018. PMID: 29741758. doi:10.1111/bjh.15262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。